A breakthrough in treating an aggressive form of prostate cancer could boost survival rates, according to new research. American scientists have identified a gene that drives the development of ...

AstraZeneca Plc AZN received two significant regulatory updates from the U.S. Food and Drug Administration, with its cancer ...

Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while ...

Metastatic androgen pathway modulation-naïve or -sensitive prostate cancer was previously referred to as metastatic hormone-sensitive prostate cancer.

Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while enhancing antitumor ...

June 2026 Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer Based on results of CAPItello-281 which prospective ...

The breakthrough at Columbia University lays the groundwork for future clinical studies aimed at developing new treatments.

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

New prostate cancer research from an international team led by the Center for Genetic Epidemiology at the Keck School of Medicine of USC has yielded discoveries that could improve screening and ...

Here in the United States, prostate cancer is the second most diagnosed cancer in men, behind only skin cancer. Almost 13% of ...

New prostate cancer research from an international team led by the Center for Genetic Epidemiology at the Keck School of Medicine of USC has yielded discoveries that could improve screening and ...